Abstract:Biologic therapy has revolutionized the treatment of inflammatory bowel disease (IBD). Nevertheless, it is well known that biologics are associated with an increased risk of opportunistic infections such as tuberculosis (TB). Screening tests indicated before biologic initiation, namely interferon gamma release assay (IGRA) or tuberculin skin tests (TST), may be falsely negative. We present the case of a male with uncontrolled Crohn's disease (CD) with a negative screen for TB and how a high index of suspicion led to the discovery of latent tuberculosis infection (LTBI) and the appropriate deferment of biologic therapy. A 63-year-old South Asian male with coronary artery disease status post bypass graft, prostate cancer, diabetes and iron deficiency anemia presented with fatigue and dizziness for one week. He reported dark stools since immigration from Bangladesh two years ago. Vital signs and examination were unremarkable. Laboratory studies revealed a gradual decline in hemoglobin from 9 g/dL to 7 g/dL over several months. Esophagogastroduodenoscopy was unremarkable. Colonoscopy revealed friability, inflammation and erythema of the ileocecal valve and terminal ileum (TI) with minimal strictures. Biopsy was consistent with CD. He was started on azathioprine. Subsequent computed tomography (CT) enterography revealed thickened TI extending over a length of 9-10 centimeters. Due to disease severity and continued symptoms, he was referred to our tertiary care center where it was determined that he may benefit from biologic therapy. Patient underwent IGRA testing which was negative. Given his immigration from an endemic area and use of immunosuppressants, a CT of the chest was obtained which was significant for tree-in-bud opacities within the right upper lobe and multiple nodules. Transbronchial biopsy of the largest nodule showed necrotizing granulomatous inflammation. Bronchoalveolar lavage culture was positive for Mycobacterium tuberculosis. The patient was diagnosed with LTBI. Anti-tuberculin therapy was initiated, and biologic therapy was postponed. Biologic agents are increasingly utilized in the treatment of IBD. These agents confer an increased risk of infections i.e. TB and poor outcomes from severe disease. Patients with IBD are also susceptible to infections due to the immunosuppression imposed by the disease itself. The risk of TB varies with the biologic used with the highest relative risks associated with adalimumab and infliximab. Screening for LTBI is indicated in all patients for which biologics are being considered. The goal is to identify and treat individuals at high risk for TB reactivation. A thorough history and examination should be performed to assess pertinent signs and symptoms. While IGRA has demonstrated higher sensitivity and specificity compared to TST, immunosuppressed patients may have a false negative result as in our case. Combination testing may be the most sensitive approach though evidence is limited. In cases of high suspicion, imaging with plain radiograph or CT scan is a useful tool in supporting the diagnosis of LTBI and may show predominantly upper lobe cavitary disease. Biologic therapy for IBD should be deferred until at least one month of treatment for LTBI has been completed.

P1111 Prevalence and risk factors for active tuberculosis in Tunisian IBD patients

S1498 Prevalence and Outcomes of Active and Latent Tuberculosis Among Patients With Inflammatory Bowel Disease (IBD) in an Endemic Region

P502 Different Presentation of Tuberculosis Associated with Anti-Tnf Therapy among Patients with Inflammatory Bowel Disease in Endemic Area: Observation from China

Altered Intestinal Microbiota and Fecal Metabolites in Patients with Latent and Active Pulmonary Tuberculosis

P568 Does Infliximab Therapy Increase Incidence of Tuberculosis in Patients with Inflammatory Bowel Disease in an Endemic Area: a Nationwide Study from China

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening

P040 Latent Tuberculosis Infection In A Patient With A Negative Interferon Gamma Release Assay Prior to Biologic Initiation for Crohn's Disease

Investigation on status quo of tuberculosis screening in 1711 patients with inflammatory bowel diseases before infliximab therapy in China

Demographic, Clinical, Radiological, and Surgical Outcome of Patients with Intestinal Tuberculosis: A Single-Center Retrospective Study

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study

A regression predictive model for QuantiFERON-TB Gold Plus® indeterminate results in immunosuppressed patients

how useful is the tuberculin skin test for the detection of active tuberculosis: Assessing diagnostic accuracy metrics and selection of best cut-off value through a large Tunisian multicenter case-control study

Tuberculosis Screening Using IGRA and Chest Computed Tomography in Patients with Inflammatory Bowel Disease: A Retrospective Study.

P980 Dietary perceptions and practices in patients with Inflammatory Bowel Disease

The T-SPOT.TB Assay Used for Screening and Monitoring of Latent Tuberculosis Infection in Patients with Behçet's Disease Pre- and Post-Anti-tnf Treatment: A Retrospective Study.

Prevalence of Intestinal Parasitic Infections and Associated Factors among Presumptive Pulmonary Tuberculosis Patients at Debre Tabor Referral Hospital, South Gondar, Northwest Ethiopia: A Cross-Sectional Study

Pulmonary tuberculosis incidence, trends and predictions in Monastir, Tunisia (2000-2030)

Performance of Interferon-gamma Release Assay for Tuberculosis Screening in Inflammatory Bowel Disease Patients

Tuberculosis in southern Morocco: Retrospective analysis from 2006 to 2012

LATENT TUBERCULOSIS IN PATIENTS WITH CROHN'S DISEASE IN A UNIVERSITY HOSPITAL IN NORTHEASTERN BRAZIL: A RETROSPECTIVE STUDY